AmyriAD Therapeutics is focused on developing innovative therapies for Alzheimer's Disease (AD), with a particular emphasis on their lead compound, AD101. This investigational oral treatment is designed to enhance global function and cognition in AD patients by modulating specific T-type calcium channels, which promotes the release of acetylcholine, a crucial neurotransmitter in the brain. AD101 is intended to be used in conjunction with Donepezil (Aricept®), the current standard of care for AD, to provide additive benefits. Clinical trials have shown that AD101, when combined with Donepezil, results in statistically significant improvements in cognitive function and global performance compared to Donepezil alone, while maintaining a safety profile similar to that of the placebo.

In addition to their therapeutic efforts, AmyriAD is also advancing diagnostic technologies aimed at detecting structural changes in proteins associated with AD. Their approach includes the development of digital staging assessments to modernize the evaluation of disease severity and treatment impact. By integrating cutting-edge diagnostics with their drug development initiatives, AmyriAD aims to provide a comprehensive strategy for managing Alzheimer's Disease, focusing on early diagnosis, effective treatment, and improved patient quality of life.

United States

AmyriAD Therapeutics is a privately held, late clinical-stage pharmaceutical development company focused on advancing effective therapies for Alzheimer's Disease (AD). The company's leadership has a legacy of success in AD drug development and brings together decades of experience in AD with the singular goal of developing innovative treatments for this debilitating condition.

AmyriAD Therapeutics

Company Details